DDInter703 DDInter899
Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. Etravarine must always be used in combination with other antiretroviral drugs. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Etravirine {u} (Compound) resembles {v} (Compound) Rilpivirine
Etravirine {u} (Compound) binds {v} (Gene) ABCB1
Etravirine {u} (Compound) is included by {v} (Pharmacologic Class) Non-Nucleoside Analog
Etravirine {u} (Compound) causes {v} (Side Effect) Disturbance in attention
Etravirine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Etravirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Etravirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Etravirine {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Etravirine {u} may lead to a major life threatening interaction when taken with {v} Cobimetinib
Etravirine (Compound) resembles Rilpivirine (Compound)
Etravirine (Compound) binds ABCB1 (Gene)
Etravirine (Compound) is included by Non-Nucleoside Analog (Pharmacologic Class)
Etravirine (Compound) causes Disturbance in attention (Side Effect)
Etravirine may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Etravirine may lead to a major life threatening interaction when taken with Encorafenib
Etravirine may lead to a major life threatening interaction when taken with Cobimetinib